Objective. A major barrier to genetic studies of osteoarthritis (OA) is the need to obtain large numbers of individuals with standardized radiographic evaluations for OA. To address this gap, we performed a genome-wide association study (GWAS) of radiographically defined tibiofemoral knee OA in 3,898 cases and 3,168 controls from 4 well-characterized North American cohorts, and we performed replication analysis of previously reported OA loci.
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Despite numerous efforts to identify genetic factors associated with OA, robust replication of findings has been difficult. This is likely due to the highly heterogeneous nature and phenotype specificity of OA, as well as potentially different environmental effects on weight-bearing and non-weight-bearing joint sites (14) . The genetic architecture of OA likely involves many loci, each having a small effect size. Nevertheless, identifying even small effect size loci may provide insights into aspects of etiology and pathogenesis of OA that in some cases may suggest targets for prevention and treatment. A major barrier to large-scale genetic studies of OA has been the difficulty of obtaining large numbers of subjects who have undergone rigorous phenotyping using standardized evaluation. To address this gap, we performed a 2-stage GWAS of radiographically defined tibiofemoral knee OA in 3,898 cases and 3,168 controls from 4 well-characterized North American OA cohorts. We also evaluated evidence for the association of knee OA with previously reported OA loci.
PATIENTS AND METHODS
We conducted a GWAS of radiographic tibiofemoral knee OA in Caucasian subjects using a 2-stage design. Stage 1 (discovery) consisted of a GWAS meta-analysis carried out in 2 independent populations: the Osteoarthritis Initiative (OAI) and the Johnston County Osteoarthritis Project. In stage 2 (validation), lead singlenucleotide polymorphisms (SNPs) from the most significantly associated loci identified from the meta-analysis were genotyped and tested for association in 2 independent cohorts: the Multicenter Osteoarthritis Study (MOST) and the Genetics of Osteoarthritis study. Finally, we conducted a full meta-analysis of the lead SNPs by combining study results from all 4 cohorts. Knee OA was evaluated with fixed-flexion posteroanterior (PA) radiographs. Knee OA was defined as having definite osteophytes and possible joint space narrowing (Kellgren/Lawrence [K/L] grade $2 [15] ) or total joint replacement in one or both knees. We defined controls as having no or doubtful evidence of OA in both knees (K/L grade 0 or 1) at all available time points. The same definitions for cases and controls were used in stage 1 and stage 2 analyses.
Stage 1 cohorts included 2,672 cases (2,014 from the OAI and 658 from the Johnston County Osteoarthritis Project) and 1,776 controls (953 from the OAI and 823 from the Johnston County Osteoarthritis Project). Discovery loci that met P # 1 3 10 24 in stage 1 were brought forward for de novo genotyping in stage 2 cohorts. Stage 2 cohorts included 1,226 cases (709 from the MOST study and 517 from the Genetics of Osteoarthritis study) and 1,392 controls (405 from the MOST study and 987 from the Genetics of Osteoarthritis study). In total, there were 3,898 cases and 3,168 controls. We considered associations to be significant at a genome-wide level if they reached P , 5 3 10 28 in the combined meta-analysis of stage 1 and stage 2 results.
Discovery cohorts. OAI. The OAI is a prospective longitudinal study designed to identify risk factors for the incidence and progression of symptomatic tibiofemoral knee OA. A total of 4,796 men and women of any race/ethnicity ages 45-79 years were enrolled into predefined progression or incidence subcohorts (16) . Briefly, the progression subcohort included individuals who had symptomatic radiographic knee OA, while the incidence subcohort included individuals who were considered to be at increased risk of developing symptomatic radiographic knee OA based on weight, knee symptoms, history of knee injuries/surgeries, family history of knee replacement, and hand OA. Participants were recruited at 4 different clinical sites: Brown University (Providence, RI); The Ohio State University (Columbus, OH); University of Maryland and The Johns Hopkins University (Baltimore, MD); and University of Pittsburgh (Pittsburgh, PA). Details of the study protocol, including recruitment procedures and eligibility criteria, are available on the OAI web site (http:// oai.epi-ucsf.org/datarelease/docs/StudyDesignProtocol.pdf).
A total of 4,492 subjects ages 45-79 years underwent bilateral PA weight-bearing fixed-flexion knee radiographs at baseline between 2004 and 2006 and were invited back to assess incidence or progression of OA annually for up to 96 months. We restricted analyses to centrally read annual assessments up to 48 months. Data release versions for central image assessments were version 0.5 for baseline, 1.5 for the 12-month visit, 3.4 for the 24-month visit, 5.4 for the 36-month visit, and 6.2 for the 48-month visit. For this study, radiographs obtained at baseline were used to define OA cases; baseline and follow-up radiographs were used to define controls.
Johnston County Osteoarthritis Project. The Johnston County Osteoarthritis Project is an ongoing, community-based study of the occurrence of knee and hip OA in African American and Caucasian residents age $45 years in a rural county in North Carolina. A detailed description of participant recruitment has been reported (17) . Briefly, participants were recruited by probability sampling, with oversampling of African Americans. A total of 3,068 individuals were recruited at baseline. Similar to the OAI, cases in the Johnston County Osteoarthritis Project were defined at baseline (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) , and controls were required to be OA-free at baseline and at up to 2 subsequent follow-up examinations (1999-2004 and 2006-2010) . The current analysis includes 1,481 Caucasian participants with genotype data and radiographic information obtained from weight-bearing anteroposterior (AP) extended radiographs at baseline and fixed-flexion PA radiographs at follow-up. There is substantial concordance by K/L grade between AP extended and PA fixed-flexion radiographs (18) .
Validation cohorts. MOST. The MOST study is a longitudinal, prospective, observational study of knee OA in older individuals from the general population who either have OA or are at increased risk of developing knee OA based on weight, knee symptoms, or history of knee injuries/surgeries (19) . Additional information regarding recruitment and study protocols is Genetics of Osteoarthritis study. The Genetics of Osteoarthritis study is a case-control-based genetic association study of OA. The goal of this study was to identify genetic variations associated with OA, with careful attention to rigorous phenotyping of controls in the same manner as the cases (20) . The Genetics of Osteoarthritis study recruited ;1,000 Caucasian participants with hand OA with or without OA in the knees, hips, and lumbosacral spine as well as 1,000 unaffected controls of similar age, sex, and ethnicity.
Genotyping. Participants in the OAI were genotyped on an Illumina Omni-Quad 2.5M array at the Translational Genomics Research Institute (Phoenix, AZ), and participants in the Johnston County Osteoarthritis Project were genotyped on an Illumina Infinium 1M-Duo bead array at Expression Analysis (Morrisville, NC). Genotypes for both studies were called using Illumina BeadStudio software. The total number of genotyped SNPs was 2,440,283 in the OAI and 1,199,187 in the Johnston County Osteoarthritis Project.
Samples that had call rates across all SNPs of ,95% were removed (185 samples in the OAI and 13 samples in the Johnston County Osteoarthritis Project). We additionally excluded from analysis potentially problematic samples based on 1) apparent mismatches between self-reported and genetically determined sex or 2) detection of second-degree or higher relationships with other samples (56 samples in the OAI and 40 samples in the Johnston County Osteoarthritis Project). We excluded an additional 34 OAI samples in which we detected large chromosomal abnormalities using log-R ratio and B allele frequency, as described by others (21) (22) (23) . Genotypes for both cohorts were imputed to the 1000 Genomes Project reference panel for Utah residents with ancestry from northern and western Europe (June 2011 release) using the Minimac software program (http:// genome.sph.umich.edu/wiki/Minimac), resulting in a total of 8,248,570 and 8,349,255 imputed SNPs in the OAI and the Johnston County Osteoarthritis Project, respectively, available for analyses after removal of SNPs with low minor allele frequencies (,1%) and poor imputation quality scores (,0.3).
Genotyping for stage 2 was performed at the Translational Genomics Research Institute on a customized Illumina array, which was designed to capture 49 top loci (P # 1 3 10 24 ) identified in stage 1 and previously reported OA variants from large-scale GWAS (9, 24) . We removed SNPs with call rates ,99% and samples with genotyping rates ,97%. Furthermore, SNPs with deviation from HardyWeinberg equilibrium (P , 1 3 10
24
) and minor allele frequencies ,1% were removed.
Statistical analysis. Association analysis for the OAI and the Johnston County Osteoarthritis Project were conducted using PLINK (http://pngu.mgh.harvard.edu/;purcell/plink/) and ProbABEL (http://www.genabel.org/packages/ProbABEL), respectively, with adjustment for baseline age, sex, study site, and principal components (PCs). PCs estimated from the genetic data were included to account for unobserved population substructure and were derived from the genome-wide SNPs, following linkage disequilibrium (LD) pruning and removal of SNPs with minor allele frequencies ,5%. Only SNPs that had minor allele frequencies $1% and imputation quality scores $0.3 were included in stage 1 analyses. Inverse variance fixed-effects meta-analysis was carried out using METAL (25) , which weights the contribution of both studies by the observed standard error. Heterogeneity between studies was assessed using Cochran's Q statistic.
We performed a meta-analysis of genome-wide association results from the OAI and the Johnston County Osteoarthritis Project and brought forward the most strongly associated loci (P # 10
) for de novo genotyping on a customized array in 2 independent cohorts, the MOST study cohort and the Genetics of Osteoarthritis study cohort. These top loci were pruned so that only the most significant SNP in a pair of SNPs in high LD, r 2 . 0.8, was selected. If the selected SNP could not be genotyped, then the second most significant SNP was selected or a proxy in high LD, r 2 . 0.8, was chosen as a tag SNP. We also performed association analysis of previously reported OA loci including 3 knee OA loci (10-13) and 8 loci from the Arthritis Research Council Osteoarthritis Genetics (arcOGEN) study (9) . After validation analyses of top loci and previously reported loci in stage 2, we then combined results from stage 1 and stage 2 in a meta-analysis to determine whether any loci from stage 1 could be elevated to genome-wide significance with the addition of data from stage 2. We also performed secondary analyses adjusting for body mass index (BMI) and history of knee injury or surgery.
Odds ratios (ORs) are provided with 95% confidence intervals (95% CIs). We estimated that our 2-stage design totaling 3,898 cases and 3,168 controls provided 80% power to detect ORs ranging from 1.24 to 1.39 for OA-associated SNPs at an alpha level of 5 3 10 28 (i.e., conventional thresholds for genomewide statistical significance) across a range of allele frequencies, and ORs ranging from 1.13 to 1.24 for OA-associated SNPs at an alpha level of 1 3 10
25
.
RESULTS
Our sample included 2,672 cases and 1,776 controls in stage 1 (discovery) and 1,226 cases and 1,392 controls in stage 2 (validation); all participants were self-reported Caucasians. In total, there were 3,898 cases and 3,168 controls in the full meta-analysis across stages 1 and 2. Clinical characteristics of participants in stage 1 (the OAI and the Johnston County Osteoarthritis Project) and stage 2 (the MOST study and the Genetics of Osteoarthritis study) are provided in Table 1 . OA patients had a mean age of 63-64 years in the OAI, Johnston County Osteoarthritis Project, and MOST study, and a mean age of 72 years in the Genetics of Osteoarthritis study. Compared to controls, a greater proportion of OA patients were women in both the OAI (56% versus 54%) and the MOST study (60% versus 54%). The proportion of women was similar between OA patients and controls in the Johnston County Osteoarthritis Project (61%) and the Genetics of Osteoarthritis study (70%). Across all studies, OA patients had a higher BMI than controls (OAI, 29 Following GWAS in the discovery set, we identified 823 SNPs associated with knee OA at a P value threshold of #1 3 10
24
. We used LD pruning (removing SNPs with r 2 , 0.80 to an already captured SNP) to reduce this number to 49 uncorrelated SNPs. We carried forward these 49 unique loci for de novo genotyping in the MOST study and the Genetics of Osteoarthritis study. In secondary analyses, we included additional adjustments for BMI and history of knee injury or surgery, which resulted in no-to-slight attenuation of top associations (P , 1 3 10
Stage 2 (validation
Cases (n 5 2,014) Controls (n 5 953) Cases (n 5 658) Controls (n 5 823) Cases (n 5 709) Controls (n 5 405) Cases (n 5 517) Controls (n 5 987) Age at baseline, mean 6 SD years 63.1 6 9.0 59.5 6 9.1 63.1 6 10.4 58.3 6 9.1 64.3 6 7.7 60.8 6 7.2 72.5 6 8.3 68.0 6 7.8 Women, % 55.7 54.0 61.1 61.2 59.9 54.1 69.6 70.5 BMI, mean 6 SD kg/m 2 29.0 6 4.6 27.0 6 4.3 30.2 6 6.0 28.0 6 5.3 31.4 6 5.9 28.4 6 4.3 28.9 6 5.6 26.9 6 4.7 Weight, mean 6 SD
25
) in the combined stage 1 and stage 2 meta-analysis (Table 3) . Four loci reached suggestive significance (P , 1 3 10
) only after adjusting for BMI (rs7079380 and rs11258527 in FRMD4A) and history of knee injury/surgery (rs6963954 in NOD1 and rs974515 near CRBN/LRRN1) ( Table 3) .
Replication of previously reported OA loci. We also tested associations between previously reported OA SNPs that were significant at a genome-wide level or replicated across several studies (9-13) that were mostly conducted in European cohorts. We detected nominally significant associations (P , 0.05) with 3 of 11 previously reported OA SNPs: rs143383 in GDF5 (OR 1.12 [95% CI 1.04-1.21], P 5 2.13 3 10 * OA 5 osteoarthritis; Chr. 5 chromosome; OR 5 odds ratio; 95% CI 5 95% confidence interval; TJR 5 total joint replacement; THR 5 total hip replacement; TKR 5 total knee replacement. † Not genotyped in the validation cohorts, but is in linkage disequilibrium with rs6087704 (r 2 5 0.96), which was genotyped; meta-analysis association results are presented for rs6087704. ‡ rs6976 and rs11177 represent the same signal (r 2 5 1). § Genotyped, but did not pass quality control.
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YAU ET AL observed for GDF5 and FTO, but not CHST11, were directionally consistent with previously reported effects (Table 4) . Notably, the ORs at all loci estimated in our study were smaller than the reported results.
DISCUSSION
We performed the largest and most comprehensive GWAS of radiographic tibiofemoral knee OA yet to be carried out in North American Caucasians, incorporating 4 independent cohorts and a 2-stage design. Our study provides suggestive evidence of a novel knee OA locus on chromosome 5p13 near LSP1P3 (lymphocyte-specific protein 1 pseudogene 3), which has not been identified by any other GWAS to date. In contrast to previously reported large-scale OA GWAS, which largely included patients who underwent total joint replacement, our study focused particularly on patients with tibiofemoral knee OA defined radiographically by definite osteophytes and possible joint space narrowing; fewer than 5% had total joint replacements. We also provide modest replication for 3 previously reported OA loci, including GDF5, CHST11, and FTO. Even with a large sample size of 3,898 cases, we did not identify any loci at genome-wide levels of significance and replicated only 3 loci at nominal levels of significance. These findings highlight the polygenic nature of knee OA and the need for even larger studies to achieve sufficient power to detect small effect sizes.
Similar to other complex diseases, the genetic architecture of OA is characterized by many common genetic variants (minor allele frequencies .5%) with small effect sizes. So far, only a dozen genome-wide significant loci have been identified for knee and hip OA in European Caucasians, ranging in effect sizes from 1.12 to 1.28 (26) . The largest GWAS of OA to date was conducted by the arcOGEN study in the UK, which included 7,410 cases and ;11,000 population controls (9) . The arcOGEN study identified 5 novel loci of genome-wide significance (GLT8D1/GNL3, ASTN2, FILIP1/SENP6, KLHDC5/ PTHLH, and CHST11) and 3 novel loci of near genomewide significance (TP63, FTO, and SUPT3H/CDC5L). Of these 8 loci, we replicated only 2, the CHST11 locus and the FTO locus, despite having enough statistical power to detect ORs .1.10 at nominal significance. One possible explanation for this is that some of the OA-associated loci reported in the arcOGEN study were specific to hip OA, and some were only significant in subanalyses restricted to men or women. We also used a slightly different, less severe, radiographic tibiofemoral knee OA phenotype. Fewer than 5% of our patients had total knee replacements, while the majority of OA patients in the arcOGEN study (;80%) had total hip and/or knee replacements.
One of the major challenges facing genetic studies of knee OA is the high degree of phenotype heterogeneity that exists due to differences in phenotype definition. Recent efforts have focused on standardizing phenotype definitions across genetic studies of OA so as to reduce phenotype heterogeneity and facilitate replication (14) . Both symptomatic and radiographic definitions are used in genetic studies of OA and may yield different associations. Furthermore, even within the commonly used K/L grading system for radiographic OA, K/L grades may be interpreted differently across cohorts. For example, in the Translational Research in Europe Applied Technologies for Osteoarthritis consortium, there were at least 3 different interpretations of K/L grade 2, including "one definite osteophyte," "definite osteophytes," and "definite osteophytes with possible joint space narrowing" (14) . In our study of North American OA cohorts, radiographic knee OA was defined as definite osteophytes with possible joint space narrowing at the tibiofemoral joint, the classic interpretation of K/L grade 2 knee OA (15) . This definition was standardized across all cohorts to limit phenotype heterogeneity and improve power to detect genetic associations.
Another source of phenotype heterogeneity may be confounding by risk factors that contribute to OA liability. A significant proportion of patients and controls in this analysis had a history of previous knee injury, one of the primary risk factors for knee OA aside from advanced age, overweight, obesity, and female sex (27) . There are several models by which knee trauma may affect genetic associations. One model may consider knee trauma as an independent risk factor for OA that does not operate through genetics and is itself sufficient for putting one on the path to OA. Under this model, the most appropriate analysis would be not to adjust for history of knee trauma, as this assumes that the impact of OA susceptibility loci would be identical in those with and those without knee injury, but rather to exclude those with knee injury. A second model is that OA risk alleles influence OA risk independently of prior knee trauma. Under this model, adjustment for prior knee injury should not alter the effects of OA risk loci on OA risk. Yet a third model is that knee trauma provides a permissive milieu in which OA risk alleles are more likely to be expressed. Under this model, a follow-up analysis that adjusts for the effect of prior knee injury on OA risk should attenuate the effects of these loci. Associations with our top meta-analysis finding and replicated findings in GDF5, CHST11, and FTO remained largely unchanged after adjusting for knee trauma, suggesting that these loci operate independently of prior knee trauma. While history of knee injury or surgery may not necessarily lead to posttraumatic OA, our findings are consistent with other reports that the genetic contributions to posttraumatic and nontraumatic knee OA may be similar (28) .
The strength of our GWAS is in fact the careful phenotyping of all subjects using standardized radiography methods across all 4 meta-analysis cohorts and the availability of longitudinal data to radiographically confirm the absence of knee OA in controls at all follow-up examinations over an average of 5 years. However, the time between the initiating event and onset of knee OA is often much longer. Controls were younger than patients, and it may be only a matter of time before they develop knee OA. It is therefore possible that individuals classified as controls may eventually become patients at a later time point than we were able to capture from existing longitudinal data. This is especially relevant to the OAI and MOST studies, which ascertained participants who either have or are at high risk of symptomatic OA. Controls from the OAI and the MOST study may be more likely to be misclassified as disease-free than controls from the Johnston County Osteoarthritis Project and the Genetics of Osteoarthritis study, resulting in less power to detect significant associations. Including older, disease-free controls without predisposing risk factors would be ideal and would help reduce misclassification bias.
While one of the strengths of our analysis was the standardized radiographic assessment of knee OA across all 4 studies, the major limitation was the small sample size. Even with nearly 4,000 cases, we were powered to detect ORs of only 1.24 to 1.39 at genome-wide levels of significance. ORs for prior loci associated with knee OA range from 1.12 to 1.28. Since genome-wide genotyping was only available for the OAI and the Johnston County Osteoarthritis Project studies, we were limited to a 2-stage GWAS, which has less power than a single-stage GWAS with the same number of samples. Also, stage 2 was smaller in sample size than stage 1 and had less power to detect significant associations, further hampering replication. Additional large replication samples will be needed to increase sample size and power to elevate small-effect loci from suggestive to genome-wide significance.
In summary, we conducted the largest GWAS study of tibiofemoral knee OA in North American Caucasian OA cohorts to date based on standardized radiographic phenotypes. Our study validated 3 previously reported OA-associated loci in GDF5, CHST11, and FTO, the latter likely exerting its effects through BMI (29) . The small effect sizes identified in this study are consistent with the highly polygenic nature of knee OA, and even larger scale GWAS meta-analyses of knee OA will be needed to provide genome-wide statistical evidence.
